Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | ELF3 | P78545 | 2/20 | 0.40 |
| ▸ | MED23 | Q9ULK4 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216663 | 0.95 | CA1 (0.51) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL18720047 | 0.95 | CA1 (0.51) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15216676 | 0.94 | CA1 (0.51) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15216690 | 0.93 | HTR3A (0.43) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15218363 | 0.90 | CA1 (0.50) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15218283 | 0.89 | CA1 (0.50) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15216670 | 0.88 | CA1 (0.49) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15216685 | 0.86 | HDAC3 (0.48) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15218282 | 0.83 | CA1 (0.48) | CA12CA1CA2CA9HTR3A | |
| SCHEMBL15216675 | 0.82 | HDAC3 (0.48) | CA12CA1CA2CA9HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170102387-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | ACADEMIA SINICA (TW) | 2017-04-13 | — | — | US | disclosed |
| US-20130225532-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | ACADEMIA SINICA (TW) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225532-A1 | ZANAMIVIR PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY AND DETERMINING OSELTAMIVIR SUSCEPTIBILITY OF INFLUENZA VIRUSES | NEU1, NEU3, NEU4 | CA12 923/4885CA1 1685/4885CA2 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.